Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 275 participants.
Also called NCT06688123
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 275 participants
- Registry
-
NCT06688123
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06688123. Randomized; no masking; primary purpose treatment. Start 2025-01-08 (actual); primary completion 2026-04-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- SHR-3167
- Intervention (Drug)
- SHR-3167
- Intervention (Drug)
- Insulin glargine
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct06688123- Content hash
0589acf3cb2744c13b3e8ddda8003528f157db6a7f879f8f2df3295bd03066b1